Skip to main content
main-content
Top

06-13-2019 | Insulin degludec/Liraglutide | ADA 2019 | Article

Expert commentary: The DUAL VIII trial

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).


More on this topic

News story | IDegLira delays need for treatment intensification over glargine
News story | Support for add-on IDegLira in SGLT2 inhibitor-treated type 2 diabetes
News story | Real-world data confirm benefits of IDegLira​​​​​​​

Related topics

CME-accredited webcast

Learn more about real-world evidence of new GLP-1RAs with Melanie Davies, Stewart Harris & Takashi Kadowaki

Image Credits